KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Resmed (RMD) EBITDA (2016 - 2025)

Resmed (RMD) has disclosed EBITDA for 17 consecutive years, with $491.7 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, EBITDA rose 17.84% year-over-year to $491.7 million, compared with a TTM value of $1.8 billion through Dec 2025, up 16.58%, and an annual FY2025 reading of $1.8 billion, up 27.57% over the prior year.
  • EBITDA was $491.7 million for Q4 2025 at Resmed, up from $446.5 million in the prior quarter.
  • Across five years, EBITDA topped out at $491.7 million in Q4 2025 and bottomed at $223.4 million in Q1 2021.
  • Average EBITDA over 5 years is $327.0 million, with a median of $284.6 million recorded in 2022.
  • The sharpest move saw EBITDA decreased 1.82% in 2023, then surged 51.67% in 2024.
  • Year by year, EBITDA stood at $248.7 million in 2021, then increased by 12.66% to $280.2 million in 2022, then decreased by 1.82% to $275.1 million in 2023, then soared by 51.67% to $417.2 million in 2024, then rose by 17.84% to $491.7 million in 2025.
  • Business Quant data shows EBITDA for RMD at $491.7 million in Q4 2025, $446.5 million in Q3 2025, and $454.5 million in Q2 2025.